Abionyx: CSL Behring fails in heart disease trial -February 16, 2024 at 08:05 am EST

On Thursday, Toulouse-based biotech Abionyx Pharma welcomed the failure of a Phase 3 trial conducted by CSL Behring, a setback which, in its view, validates its recent strategic repositioning.The...

Related Keywords

Paris ,France General ,France ,Abionyx Pharma , ,Paris Bourse ,Markets ,